Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

Area of Science:

• Biotechnology
• Molecular Biology
• Drug Development

Background:

• Antisense oligonucleotides (ASOs) represent an emerging therapeutic class targeting disease at the RNA level.
• ASOs offer a promising alternative to traditional therapies by modulating protein expression through sequence-specific RNA binding.
• Challenges in ASO therapy include off-target effects and insufficient biological activity, necessitating advancements in chemical modifications and delivery.

Purpose of the Study:

• To systematically review chemical modifications, mechanisms of action, and delivery strategies for various ASO classes.
• To highlight recent advancements in ASO-based drug development, including FDA and EMA approved therapies.
• To discuss promising ASO drug candidates in clinical trials and the therapeutic potential of microRNAs.

Main Methods:

• Systematic literature review of chemical modifications and delivery strategies for antisense oligonucleotides.
• Analysis of approved ASO-based drugs and ongoing clinical trial candidates.
• Exploration of microRNA as a therapeutic target for future ASO applications.

Main Results:

• Several chemical modifications and delivery strategies have been developed to enhance ASO efficacy and reduce side effects.
• A growing number of ASO-based drugs have received FDA and EMA approval for clinical applications.
• MicroRNAs present a significant opportunity for future ASO-based therapeutic development.

Conclusions:

• ASO technology is advancing rapidly, with ongoing research focused on overcoming existing challenges.
• Optimized chemical modifications and delivery systems are crucial for successful ASO-based therapies.
• The therapeutic targeting of microRNAs using ASOs holds substantial promise for future drug development.